☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Arginase 1 Deficiency
Aeglea Biotherapeutics Achieves Primary Endpoint in P-III study of Pegzilarginase in patients with Arginase 1 Deficiency
December 6, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.